UPC Analytics
ENDE
Overview · Filed: May 30, 2024

UPC_CFI_231/2024

ANALYTE SENSOR DEVICES, CONNECTIONS, AND METHODS

RevocationMain Revocation ActionParis CDRevocationCase Closed
OverviewDecisionsReasoningCitationsDocumentsTimeline
Parties

Claimants

  • Sibio Technology Limited
Reps: Thomas Gniadek (Simmons & Simmons LLP); Fritz Lahtz; Oscar Lamme; Florian Laus; Diptanil Debbarma

Respondents

Reps: Wim Maas (Taylor Wessing N.V.); François Pochart (August Debouzy); Mehdi Mahammedi-Bouzina (August Debouzy)
Judges

French-seated division — individual judges anonymized.

  • Panel member (anonymized)
  • Panel member (anonymized)
  • Panel member (anonymized)
Patents
  • EP3831283
  • EP 3 831 283 B1
CPC codes: A61B5/1451, H04L67/12, A61B5/15087, A61B5/145, A61B5/150022, A61B5/150335, A61B5/14503, A61B5/6849, A61B5/0004, A61B5/14532, A61B5/150503, A61B5/150877…

Technology area: Medical Devices · CGM

Sector: Pharmaceutical & Medical

Outcome
Patent maintainedMaintained as granted
Filed: May 30, 2024
First decided: Jul 21, 2025
Language: English

Decision of the Paris Central Division dismissing the revocation action by Sibio Technology Limited against Abbott Diabetes Care Inc. concerning EP 3 831 283 B1 (glucose monitoring device / CGM sensor). All grounds for revocation (lack of novelty and inventive step) failed. The patent is maintained as granted. Abbott (defendant/patentee) awarded costs. Key headnotes: novelty and inventive step are separate grounds and cannot be combined against the same prior art; grounds for revocation of dependent claims must be stated from the outset; Rule 75(3) RoP does not apply when a counterclaim for revocation in a subsequent infringement action is filed after the oral hearing in an earlier revocation action.

Open on UPC Registry
Claims
At issueall
Maintainedall
Notes: Paris Central Division dismissed revocation action against EP3831283; all revocation grounds (lack of novelty and inventive step) failed and patent maintained as granted.